Physician profile
Heidi Mcsweeney
NPI 1063538775
$1,717.82
in general payments reported to CMS, 2019-2025
23 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Obstetrics & Gynecology (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $446 · 2022: $386 · 2023: $85.44 · 2024: $437 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $234.09 | 2021-2025 | Nexplanon |
| Abbvie INC. | $210.85 | 2021-2025 | |
| Hologic Sales and Service, LLC | $198.38 | 2021-2025 | Myosure Tissue Removal Device, Aptima |
| Evofem Biosciences, INC. | $176.02 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.50 | 2021-2025 | |
| Glaxosmithkline, LLC. | $115.37 | 2024 | Zejula |
| Ethicon US, LLC | $104.43 | 2024-2025 | Vistaseal, Stratafix, Surgicel Nu-Knit |
| Pfizer INC. | $101.68 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $93.55 | 2021-2025 | |
| Exeltis, USA INC. | $64.18 | 2021-2024 | Slynd |
| Coloplast Corp | $40.05 | 2025 | |
| Sumitomo Pharma America, INC. | $39.89 | 2025 | Myfembree |
| Biogen, INC. | $34.66 | 2024 | Zurzuvae |
| Avion Pharmaceuticals | $25.80 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $25.35 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaand Gmbh | $20.68 | 2025 | Rubraca |
| Becton, Dickinson and Company | $17.20 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $15.83 | 2024 | Bd Onclarity |
| Roche Diagnostics Corporation | $15.15 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.55 | 2022 | |
| Merck Sharp & Dohme LLC | $13.22 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.90 | 2021 | |
| Agile Therapeutics, INC. | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Mcsweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.